香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因依賴該等內容而引 致的任何損失承擔任何責任。 MUYUAN FOODS CO., LTD. 牧原食品股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向牧原食品股份有限公司（「本公司」，連同其子公司為「本集團」）、本公司的聯席保薦 人、整體協調人、顧問或承銷團成員表示同意： 倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長登記的本公 司招股章程作出投資決定。該文件的文本將於發售期內向公眾人士刊發。 (a) 本文件僅向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件所載 的資料作出任何投資決定； (b) 在聯交所網站登 ...

多轮准备后进入实质推进期 【大河财立方 记者 徐兵】牧原股份赴港上市迎来关键进展。11月27日晚间，公司公告披露，已正式收 到证监会出具的《境外发行上市备案通知书》，拟发行不超过5.46亿股H股并在香港联交所主板上市。 自今年4月首次披露H股计划以来，牧原境外上市的关键合规手续已基本完成，上市进程再上台阶。 公司高层在近期公开场合也表示：牧原走向国际市场已不仅仅局限于出口产品，而是要"参与全球猪肉 供应链竞争"。牧原相关负责人在近期的行业论坛上表示，选择香港上市，是看重香港作为全球金融中 心的国际资本集聚效应，"希望让公司在更透明、更成熟的国际市场接受估值，进一步提升国际知名度 和影响力"。 该负责人还透露，牧原正加快搭建跨国团队，而赴港上市有望在引入国际人才、拓宽融资工具、推进全 球业务协同等方面形成推进器效应。 牧原的国际化步伐背后，是其不断强化的全球行业地位。弗若斯特沙利文数据显示，自2021年以来，牧 原已连续位居全球第一大生猪养殖企业；全球市场份额从2.6%增长至2024年的5.6%。过去三年，其屠 宰与肉食业务收入增速在国内大型同行中居首，在全球前十大生猪企业中也位居第一。 在牧原对外沟通中，效率 ...

Core Viewpoint - Muyuan Foods Co., Ltd. is making significant progress in its overseas listing plans, having received a registration notice from the China Securities Regulatory Commission for its H-share issuance in Hong Kong [1][2]. Group 1: Overseas Listing Progress - The company plans to issue no more than 546 million shares for its overseas listing on the Hong Kong Stock Exchange [1]. - The registration notice requires the company to report any major events during the listing process and to update registration materials if the listing is not completed within 12 months [1][2]. - The company initiated its Hong Kong listing plan in early 2025 and submitted its application on May 27 [1]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 111.79 billion yuan, representing a year-on-year growth of 15.52%, and a net profit attributable to shareholders of 14.779 billion yuan, up 41.01% [2]. - In the third quarter, the company reported a revenue of 35.327 billion yuan and a net profit of 4.249 billion yuan [2]. Group 3: Strategic Partnerships - The company signed a strategic cooperation agreement with Charoen Pokphand Group to enhance collaboration in various sectors, including feed, pig farming, and food processing [2]. - In September, the company entered into a partnership with BAF Vietnam Agricultural Joint Stock Company to develop a high-tech pig farming project in Vietnam, with an estimated total investment of 3.2 billion yuan [2].

Core Viewpoint - Muyuan Foods has made significant progress in its plan to list H-shares in Hong Kong, having received the necessary approval from the China Securities Regulatory Commission (CSRC) for its overseas issuance and listing [1][4]. Group 1: Listing Details - The company plans to issue no more than 546,276,700 H-shares and list on the main board of the Hong Kong Stock Exchange [1]. - The issuance will account for up to 8% of the company's total share capital post-issuance, with an overallotment option of up to 15% of the issued shares [4]. Group 2: Strategic Intent - The listing is part of Muyuan's strategy to enhance its international presence and create a global capital operation platform, aiming to diversify financing channels and tools [5]. - The funds raised will primarily be used for product research and development, overseas market expansion, strategic investments, and to supplement working capital [4]. Group 3: Market Position - Muyuan Foods is recognized as the world's largest pig farming enterprise by production capacity and slaughter volume since 2021, with a global market share in pig slaughtering increasing from 2.6% in 2021 to 5.6% in 2024 [5]. - The company has established strategic partnerships with local farming companies in Vietnam, indicating its commitment to expanding its international operations [4].

Core Viewpoint - Muyuan Foods Co., Ltd. has received a notice from the China Securities Regulatory Commission regarding its plan to issue up to 546 million overseas listed ordinary shares and list them on the Hong Kong Stock Exchange [1] Group 1 - The company plans to issue no more than 546 million shares for overseas listing [1] - The issuance is subject to reporting any significant events to the China Securities Regulatory Commission through the designated management information system [1] - The company must report the status of the issuance and listing within 15 working days after the completion of the overseas listing [1] Group 2 - If the overseas listing is not completed within 12 months from the date of the notice, the company must update its filing materials to continue the process [1]

智通财经APP讯，牧原股份(002714.SZ)公告，公司正在进行申请境外上市外资股(H股)发行并在中国香 港联合交易所有限公司主板挂牌上市的相关工作。公司近日已收到中国证监会出具的《关于牧原食品股 份有限公司境外发行上市备案通知书》。 ...

格隆汇11月27日丨牧原股份(002714.SZ)公布，公司正在进行申请境外上市外资股（H股）发行并在香港 联合交易所有限公司（简称"香港联交所"）主板挂牌上市的相关工作。公司于近日收到中国证券监督管 理委员会（简称"中国证监会"）出具的《关于牧原食品股份有限公司境外发行上市备案通知书》。 ...

牧原股份公告，发行境外上市外资股（H股）获得中国证监会备案。 ...

| 证券代码：002714 | 证券简称：牧原股份 | 公告编号：2025-105 | | --- | --- | --- | | 债券代码：127045 | 债券简称：牧原转债 | | 牧原食品股份有限公司（以下简称"公司"）正在进行申请境外上市外资股（H 股）发行并在香港联合交易所有限公司（以下简称"香港联交所"）主板挂牌上 市（以下简称"本次发行并上市"）的相关工作。公司于近日收到中国证券监督 管理委员会（以下简称"中国证监会"）出具的《关于牧原食品股份有限公司境 外发行上市备案通知书》（国合函〔2025〕2113 号）（以下简称"备案通知书"）。 备案通知书主要内容如下： 一、公司拟发行不超过 546,276,700 股境外上市普通股并在香港联合交易所 上市。 二、自备案通知书出具之日起至本次境外发行上市结束前，公司如发生重大 事项，应根据境内企业境外发行上市有关规定，通过中国证监会备案管理信息系 统报告。 三、公司完成境外发行上市后 15 个工作日内，应通过中国证监会备案管理 信息系统报告发行上市情况。公司在境外发行上市过程中应严格遵守境内外有关 法律、法规和规则。 四、公司自备案通知书出具之日起 ...

Core Points - The Biotech Index (970038) closed at 2134.66 points, down 0.06%, with a trading volume of 13.045 billion yuan and a turnover rate of 0.95% [1] - Among the index constituents, 22 stocks rose while 27 fell, with Hualan Vaccine leading the gainers at 2.57% and Jingxin Pharmaceutical leading the decliners at 5.97% [1] Index Constituents Summary - The top ten constituents of the Biotech Index include: - Mindray Medical (12.58% weight, latest price 196.30 yuan, market cap 238 billion yuan) [1] - Changchun High-tech (4.87% weight, latest price 99.66 yuan, market cap 40.655 billion yuan) [1] - Shimi Aoshi (4.74% weight, latest price 6.60 yuan, market cap 4.3811 billion yuan) [1] - Kanglong Chemical (4.55% weight, latest price 28.87 yuan, market cap 51.337 billion yuan) [1] - Tigermed (4.54% weight, latest price 51.20 yuan, market cap 44.085 billion yuan) [1] - Deep Technology (4.16% weight, latest price 23.42 yuan, market cap 36.809 billion yuan) [1] - Muyuan Food (3.62% weight, latest price 49.90 yuan, market cap 272.592 billion yuan) [1] - Lepu Medical (3.19% weight, latest price 15.87 yuan, market cap 29.255 billion yuan) [1] - Aimeike (3.16% weight, latest price 146.26 yuan, market cap 44.257 billion yuan) [1] - Seeyou Medical (3.07% weight, latest price 35.70 yuan, market cap 35.788 billion yuan) [1] Capital Flow Analysis - The Biotech Index constituents experienced a net outflow of 84.2481 million yuan from institutional investors, while retail investors saw a net inflow of 67.1618 million yuan [1] - Notable capital flows include: - Muyuan Food: 104 million yuan net inflow from institutional investors, but net outflows from retail and speculative investors [2] - Aimeike: 46.9918 million yuan net inflow from institutional investors, with outflows from retail and speculative investors [2] - Mindray Medical: 33.0761 million yuan net inflow from institutional investors, with outflows from retail and speculative investors [2]